-
LA JOLLA–(June 10, 2021) In order for cancer to grow and spread, it has to evade detection by our immune cells, particularly specialized “killer” T cells. Salk researchers led by […]
Jun 10,2021
-
By Joe Barone- βWhat?β It is a frustrating, one-word question many of us exclaim when something in our lives seems completely surreal. Oftentimes, itβs provoked by something so egregious and […]
Apr 28,2021
-
Mestag Therapeuticsβ’, a new company developing innovative therapies and treatments for cancers and inflammatory diseases, has been launched with $11 million in seed financing. In collaboration with Cold Spring Harbor […]
Apr 26,2021
-
Giving early-stage pancreatic cancer patients a CD40 immune-stimulating drug helped jumpstart a T cell attack to the notoriously stubborn tumor microenvironment before surgery and other treatments, according to a new […]
Apr 10,2021
-
Β Researchers testing organoids use in predicting treatment outcomes A new team of pioneering pancreatic cancer researchers has been formed to predict which treatments might work best for individual pancreatic cancer […]
Mar 30,2021
-
By Kerri Kaplan, President Stephen Grand: Pancreatic Cancer Fighter and Research Funder Our hearts are broken at the news of the passing of Lustgarten ally and donor, Stephen Grand of […]
Mar 25,2021
-
Researchers developed a prototype for a new cancer immunotherapy that uses engineered T cells to target a genetic alteration common among all cancers. The approach, which stimulates an immune response […]
Mar 15,2021
-
A novel targeted immunotherapy approach developed by researchers at theΒ Ludwig Center, theΒ Lustgarten Laboratory, andΒ Bloomberg~Kimmel Institute for Cancer ImmunotherapyΒ at theΒ Johns Hopkins Kimmel Cancer CenterΒ employs new antibodies against genetically altered proteins to […]
Mar 01,2021
